Publications

Add filters (0)

65 results

The role of type I collagen fragment C1M in knee osteoarthritis. A longitudinal biomarker study using data from the OA-FNIH consortium.

June 1, 2026

Osteoarthritis Cartilage

Abstract OBJECTIVE To evaluate the association of neoepitopes from type I and II collagen with knee osteoarthritis (OA) progression phenotypes using data from the OA-FNIH biomarker consortium, with comparison to associations of the other biomarkers assessed in this sample during the consortium’s phase 1 analysis. DESIGN Serum (s) and urinary (u) neoepitopes of type I […]

Read publication

Serum Markers of Fibroinflammatory Activity PRO-C3 and CPa9-HNE Are Associated with Liver-Related Outcomes in Patients with Chronic Hepatitis C.

May 15, 2026

J Infect Dis

Abstract BACKGROUND Chronic hepatitis C (CHC) infection remains a global health burden, contributing to the risk of long-term complications such as progressive fibrosis, cirrhosis, and hepatocellular carcinoma, particularly in undiagnosed or untreated individuals. Novel biomarkers for the assessment of disease progression and prognosis are required for fibroinflammatory chronic liver disease. Our study population from the […]

Read publication

Extracellular matrix deposition drives disease progression and reduces rapamycin response in lymphangioleiomyomatosis.

May 1, 2026

Eur Respir J

Abstract RATIONALE Lymphangioleiomyomatosis (LAM) is a rare cystic lung disease driven by nodules containing “LAM cells” and recruited LAM-associated fibroblasts. Although rapamycin reduces lung function loss, some patients continue to decline, meaning additional therapies are needed. OBJECTIVES To investigate how the LAM nodule environment affects LAM cell proliferation and the response to rapamycin. METHODS Proteins […]

Read publication

Identification of novel plasma proteomic biomarkers of Dupuytren disease.

January 1, 2026

PLoS One

Abstract Dupuytren Disease (DD) is a chronic progressive disease that can cause disabling hand deformities. The most common treatments have either high complication rates or high early recurrence rates. Dupuytren lacks a staging biomarker profile to inform the development of preventive therapeutics to improve long-term outcomes. This multi-omic study aimed to create a DD blood […]

Read publication

Basement membrane repair response biomarker PRO-C4 predicts progression in idiopathic pulmonary fibrosis: analysis of the PFBIO and PROFILE cohorts.

November 14, 2025

Thorax

Abstract BACKGROUND Idiopathic pulmonary fibrosis (IPF) is characterised by damage to the epithelial layer, closely associated with the alveolar basement membrane (BM). We aimed to investigate how type IV collagen (COL4) in the BM changes with the progression of IPF. METHODS COL4 synthesis (PRO-C4) was detected in blood by the nordicPRO-C4 biomarker in patients with […]

Read publication

Serum biochemical marker of synovial tissue turnover, C1M, predicts radiological progression in early rheumatoid arthritis.

July 10, 2025

RMD Open

Abstract OBJECTIVES To investigate whether serum C1M and C2M, biochemical markers of synovial and cartilage tissue destruction, were associated with progression of joint damage in patients with early arthritis. METHODS 813 early arthritis patients (<6 months of symptoms, 82% with rheumatoid arthritis, 18% undifferentiated arthritis) from the prospective ESPOIR study were followed for 5 years. […]

Read publication

Circulating Extracellular Matrix Products as Indicators of Disease Burden and Predictors of Disease Course in Ulcerative Colitis.

March 3, 2025

Inflamm Bowel Dis

Abstract BACKGROUND Ulcerative colitis (UC) is characterized by recurrent inflammation and challenging disease monitoring, with invasive endoscopy as the primary diagnostic tool despite the inadequacy of standard noninvasive biomarkers. This study evaluates serum extracellular matrix (ECM) fragments, which reflect the remodeling of mucosa and submucosa, as potential indicators of disease burden and treatment efficacy. We […]

Read publication

Serologic extracellular matrix remodeling markers are related to fibrosis stage and prognosis in a phase 2b trial of simtuzumab in patients with primary sclerosing cholangitis.

July 1, 2024

Hepatol Commun

Abstract BACKGROUND Novel noninvasive predictors of disease severity and prognosis in primary sclerosing cholangitis (PSC) are needed. This study evaluated the ability of extracellular matrix remodeling markers to diagnose fibrosis stage and predict PSC-related fibrosis progression and clinical events. METHODS Liver histology and serum markers of collagen formation (propeptide of type III collagen [Pro-C3], propeptide […]

Read publication

Extracellular matrix turnover proteins as risk markers in people with type 2 diabetes and microalbuminuria.

June 1, 2024

J Diabetes Complications

Abstract BACKGROUND This post-hoc study investigated whether biomarkers reflecting extracellular matrix (ECM) turnover predicted cardiovascular disease (CVD), mortality, and progression of diabetic kidney disease (DKD) in individuals with type 2 diabetes (T2D) and microalbuminuria. METHODS Serum levels of specific ECM turnover biomarkers were assessed in 192 participants with T2D and microalbuminuria from an observational study […]

Read publication

Marker for kidney fibrosis is associated with inflammation and deterioration of kidney function in people with type 2 diabetes and microalbuminuria.

January 1, 2023

PLoS One

Abstract BACKGROUND Diabetic kidney disease is a major cause of morbidity and mortality. Dysregulated turnover of collagen type III is associated with development of kidney fibrosis. We investigated whether a degradation product of collagen type III (C3M) was a risk marker for progression of chronic kidney disease (CKD), occurrence of cardiovascular disease (CVD), and mortality […]

Read publication